1. PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

   • Ronan Flippot
   • Anna Patrikidou
   • Karim Fizazi

   Review Article 05 May 2022 Pages: 719 - 733

   

2. Lupus Nephritis: Improving Treatment Options

   • Myrto Kostopoulou
   • Sofia Pitsigavdaki
   • George Bertsias

   Review Article 29 April 2022 Pages: 735 - 748

3. New Drug Delivery Systems Developed for Brain Targeting

   • Shruti U. Rawal
   • Bhoomika M. Patel
   • Mayur M. Patel

   Review Article 21 May 2022 Pages: 749 - 792

   

4. Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews

   • Salmaan Kanji
   • Sydney Morin
   • Brian Hutton

   Systematic Review 13 April 2022 Pages: 793 - 809

   

5. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC

   • Yahiya Y. Syed

   Adis Drug Evaluation 19 May 2022 Pages: 811 - 816

6. Sutimlimab: First Approval

   • Sohita Dhillon

   AdisInsight Report 12 April 2022 Pages: 817 - 823

   

7. Faricimab: First Approval

   • Matt Shirley

   AdisInsight Report 26 April 2022 Pages: 825 - 830

   

8. Pacritinib: First Approval

   • Yvette N. Lamb

   AdisInsight Report 14 May 2022 Pages: 831 - 838

   

9. Correction to: Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals

   • Fabrizio Schifano
   • Valeria Catalani
   • Amira Guirguis

   Correction 27 April 2022 Pages: 839 - 839

10. Correction to: Daridorexant: First Approval

    • Anthony Markham

    Correction Open access 27 April 2022 Pages: 841 - 841